Comparison
Noopept vs Semax
Noopept
Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Often grouped with racetams.
Semax
Russian heptapeptide derived from ACTH 4-10. Used clinically in Russia for stroke and cognitive disorders. Intranasal.
| Field | Noopept | Semax |
|---|---|---|
| Category | peptide | peptide |
| Dose range | 10–30mg | 0.3–1mg |
| Half-life | 0.5h | 0.5h |
| Onset | 20min | 15min |
| Evidence | EVIDENCEB | EVIDENCEC |
| Safety | ●●●●○ | ●●●○○ |
| Legal (US) | USUnscheduled | USResearch chemical |
| PubMed refs | 90 | 80 |
The comparison in plain English
Auto-generated from dataNoopept and Semax are both in the peptide category respectively. Noopept Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Semax Russian heptapeptide derived from ACTH 4-10.
Bottom line
Noopept (evidence B, safety 4/5) has a weaker evidence base than Semax (evidence C, safety 3/5). Noopept has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Noopept if
Noopept is the better fit when your goal aligns with its mechanism (Increases BDNF and NGF expression in the hippocampus and prefrontal cortex) and the dose range (10–30mg) suits your protocol. Half-life is 0.5h.
Choose Semax if
Semax is the better fit when your goal aligns with its mechanism (Increases BDNF and NGF expression in the hippocampus and modulates dopamine and serotonin signalling) and the dose range (0.3–1mg) suits your protocol. Half-life is 0.5h.